Neonatal Lupus Erythematosus Cell Models for Research

Neonatal lupus erythematosus (NLE) is a rare autoimmune condition affecting fetuses and newborns, caused by transplacental transfer of maternal autoantibodies against Ro/SSA and La/SSB ribonucleoproteins. The exact incidence is estimated at 1 in 12,500 to 1 in 20,000 live births, though underreporting may occur. According to the World Health Organization (WHO), autoimmune diseases collectively affect 3-5% of the global population, with NLE representing a small but significant subset. Key risk factors include maternal anti-Ro/SSA and anti-La/SSB antibodies, maternal systemic lupus erythematosus (SLE) or Sjögren's syndrome, and certain HLA alleles such as HLA-DR3 and HLA-DQ2. Clinical manifestations include congenital heart block (CHB), annular skin rash, hepatobiliary disease, and cytopenias. The mortality rate for NLE with CHB is approximately 15-30%, primarily due to complications from complete heart block and cardiomyopathy. Five-year survival for isolated cutaneous NLE is excellent (>95%), but for CHB, survival without pacing is around 70-80% at 5 years. The National Cancer Institute (NCI) does not track NLE as it is not a cancer, but the condition is monitored through pediatric rheumatology registries.

NLE serves as a valuable model for understanding autoimmune-mediated tissue damage, particularly in the context of maternal-fetal immunology. The disease offers unique insights into: (1) the role of autoantibodies in tissue injury, (2) the mechanisms of congenital heart block, and (3) the interplay between the immune system and developing organs. Subtypes include cardiac NLE, cutaneous NLE, and hepatic NLE, each with distinct pathophysiological features. Public datasets such as NCBI Gene, ClinVar, and GEO provide genomic and transcriptomic data on NLE-related genes (e.g., TRIM21, Ro60, La). Open questions include: Why do only 2-5% of anti-Ro positive pregnancies result in CHB? What are the genetic modifiers? How can we prevent autoantibody-mediated damage? These questions drive the need for robust experimental models, including gene-edited cell lines.

NLE is not a carcinogenic disease, but its pathogenesis involves immune-mediated pathways that overlap with cancer-related signaling. Key pathways include:

• • Type I interferon (IFN) pathway:

1. Maternal autoantibodies bind to fetal Ro/SSA and La/SSB antigens.

2. Immune complexes activate plasmacytoid dendritic cells.

3. Production of type I interferons (IFN-α/β) leads to tissue inflammation.

4. IFN signature contributes to cardiac fibrosis and conduction abnormalities.

• • Apoptosis and clearance defects:

1. Increased apoptosis in fetal cardiac tissues exposes Ro/La antigens.

2. Impaired clearance of apoptotic cells by macrophages leads to antigen presentation.

3. Activation of autoreactive T cells and B cells.

• • TGF-β signaling:

1. Autoantibody-mediated injury triggers TGF-β release.

2. TGF-β promotes fibrosis in the atrioventricular node.

3. Leads to congenital heart block.

• • NF-κB pathway:

1. Immune complex engagement of Fcγ receptors activates NF-κB.

2. Pro-inflammatory cytokines (TNF-α, IL-6) exacerbate tissue damage.

NLE is not typically associated with somatic mutations, but germline variants in immune-related genes influence susceptibility. The table below summarizes key genes and variants from ClinVar and NCBI Gene.

Data from ClinVar and NCBI Gene. Frequencies are approximate and based on small cohort studies.

Key signaling networks in NLE pathogenesis include:

• • Type I IFN network:
• • IFN-α/β bind to IFNAR1/2.
• • JAK-STAT pathway activation.
• • Induction of interferon-stimulated genes (ISGs) such as ISG15, MX1.
• • Contributes to cardiac inflammation and fibrosis.
• • Toll-like receptor (TLR) signaling:
• • TLR7/9 recognize RNA/DNA-immune complexes.
• • MyD88-dependent activation of NF-κB.
• • Production of pro-inflammatory cytokines.
• • TGF-β/SMAD network:
• • TGF-β binds to TGFBR1/2.
• • SMAD2/3 phosphorylation.
• • Fibrosis and extracellular matrix deposition.
• • Calcium signaling:
• • Autoantibodies against Ro/La may cross-react with L-type calcium channels.
• • Disruption of calcium homeostasis in cardiomyocytes.
• • Leads to arrhythmias and heart block.
• • Apoptosis network:
• • Fas/FasL interactions.
• • Caspase activation.
• • Exposure of autoantigens.

Several cell lines are used to study NLE mechanisms, particularly for autoantibody-mediated injury and interferon responses.

Organoid advantages: Cardiac organoids derived from iPSCs can mimic fetal heart development and autoantibody-induced damage. They provide a 3D environment for studying cell-cell interactions and fibrosis. Hepatic organoids can model NLE-related liver disease.

Animal models of NLE include:

• • Induced models:
• • Passive transfer of anti-Ro/La antibodies into pregnant mice.
• • Results in fetal heart block and skin rash.
• • Useful for testing preventive therapies.
• • Genetic models:
• • Ro60 knockout mice: Develop autoimmune features but not full NLE.
• • TLR7 transgenic mice: Show increased interferon signature.
• • C1q knockout mice: Impaired clearance of apoptotic cells.
• • Humanized models:
• • Mice engrafted with human fetal thymus and liver.
• • Reconstituted with human immune cells.
• • Allow study of human autoantibodies.
• • PDX models: Not applicable as NLE is not a cancer.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications to study NLE. Examples include:

• • TRIM21 knockout in Jurkat cells: TRIM21 is an E3 ubiquitin ligase that regulates immune signaling. Knockout lines show increased type I IFN production upon immune complex stimulation.
• • Ro60 (TROVE2) knockout in HEK293 cells: Ro60 is a major autoantigen. Knockout cells fail to bind anti-Ro antibodies, providing a tool to study autoantibody specificity.
• • La (SSB) knockout in HeLa cells: La is involved in RNA processing. Knockout lines help dissect its role in autoimmunity.
• • IFNAR1 knockout in cardiomyocytes: Blocks type I IFN signaling. Used to test whether IFN pathway is essential for autoantibody-mediated damage.
• • HLA-DR3 knock-in in iPSCs: Introduces NLE-risk HLA allele. Differentiated into cardiomyocytes to study antigen presentation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR and are available from commercial sources without naming specific companies. They enable researchers to focus on mechanistic studies rather than model generation.

Gene-edited cell lines are powerful for functional genomics in NLE:

• • Knockout of candidate genes (e.g., TRIM21, Ro60) validates their role in autoantibody production and immune activation.
• • Knock-in of disease-associated variants (e.g., HLA-DRB1*03:01) assesses their impact on antigen presentation.
• • CRISPR interference (CRISPRi) and activation (CRISPRa) screens identify regulators of interferon signaling.
• • Examples: A genome-wide CRISPR knockout screen in Jurkat cells identified TRIM21 as a negative regulator of type I IFN. Another screen in cardiomyocytes revealed calcium channel genes as modifiers of autoantibody-induced arrhythmias.

Isogenic pairs (wild-type vs. knockout) enable high-throughput drug screening:

• • Screen for compounds that block type I IFN signaling in TRIM21 knockout cells.
• • Test anti-Ro antibody-induced damage in Ro60 knockout vs. wild-type cells.
• • Model resistance to standard therapies (e.g., hydroxychloroquine) by generating resistant lines through CRISPR mutagenesis.
• • Identify drugs that prevent congenital heart block in iPSC-derived cardiomyocytes.

CRISPR synthetic lethality screens uncover genetic dependencies:

• • In NLE, synthetic lethality between Ro60 and DNA repair genes may reveal biomarkers for cardiac damage.
• • Genome-wide screens in patient-derived iPSCs identify modifiers of interferon response.
• • Biomarkers such as ISG15, MX1, and CXCL10 can be validated using reporter cell lines.
• • These approaches accelerate the development of diagnostic and prognostic markers.